Published in J Med Chem on April 08, 2010
Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94
The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One (2013) 2.43
Chemistry: Chemical con artists foil drug discovery. Nature (2014) 2.36
Probing the probes: fitness factors for small molecule tools. Chem Biol (2010) 2.08
Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase. Nat Chem Biol (2017) 2.03
Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr Opin Chem Biol (2010) 1.76
The Essential Medicinal Chemistry of Curcumin. J Med Chem (2017) 1.68
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
Covalent docking of large libraries for the discovery of chemical probes. Nat Chem Biol (2014) 1.66
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol (2015) 1.53
Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem Biol (2014) 1.52
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Natural products as starting points for future anti-malarial therapies: going back to our roots? Malar J (2011) 1.22
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A (2011) 1.22
Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci (2015) 1.21
Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO). PLoS One (2012) 1.19
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR (2013) 1.17
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). J Med Chem (2014) 1.17
Chemical predictive modelling to improve compound quality. Nat Rev Drug Discov (2013) 1.13
Colloidal aggregation causes inhibition of G protein-coupled receptors. J Med Chem (2013) 1.13
A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nat Chem (2013) 1.12
An Aggregation Advisor for Ligand Discovery. J Med Chem (2015) 1.12
Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem (2013) 1.12
The essential roles of chemistry in high-throughput screening triage. Future Med Chem (2014) 1.12
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem (2015) 1.10
ZINC 15 - Ligand Discovery for Everyone. J Chem Inf Model (2015) 1.07
Counting on natural products for drug design. Nat Chem (2016) 1.05
Comparison of small molecule inhibitors of the bacterial cell division protein FtsZ and identification of a reliable cross-species inhibitor. ACS Chem Biol (2012) 1.04
Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl Trop Dis (2012) 1.02
A small molecule screen identifies selective inhibitors of urea transporter UT-A. Chem Biol (2013) 1.02
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol (2013) 1.00
Screening-based translation of public research encounters painful problems. ACS Med Chem Lett (2015) 1.00
Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem (2013) 0.99
Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci Transl Med (2015) 0.98
Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents--real hits or promiscuous artifacts? Curr Opin Chem Biol (2010) 0.98
Growing PAINS in academic drug discovery. Future Med Chem (2011) 0.98
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem (2015) 0.97
The design and application of target-focused compound libraries. Comb Chem High Throughput Screen (2011) 0.97
Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97
Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One (2013) 0.96
Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG). ACS Chem Biol (2012) 0.95
Small molecule inhibitors of Smoothened ciliary localization and ciliogenesis. Proc Natl Acad Sci U S A (2012) 0.95
FAF-Drugs3: a web server for compound property calculation and chemical library design. Nucleic Acids Res (2015) 0.94
The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin Ther Targets (2015) 0.94
PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem. Bioinformatics (2011) 0.94
Identification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens. J Biomol Screen (2013) 0.94
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov (2016) 0.93
Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. J Med Chem (2013) 0.93
A Data Analysis Pipeline Accounting for Artifacts in Tox21 Quantitative High-Throughput Screening Assays. J Biomol Screen (2015) 0.93
Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. ChemMedChem (2011) 0.93
Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery? J Med Chem (2015) 0.93
Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov (2016) 0.92
Rational methods for the selection of diverse screening compounds. ACS Chem Biol (2011) 0.92
Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. Chem Biol (2015) 0.91
Small molecules with antiviral activity against the Ebola virus. F1000Res (2015) 0.90
Structure-Activity Relationship and Pharmacokinetic Studies of 1,5-Diheteroarylpenta-1,4-dien-3-ones: A Class of Promising Curcumin-Based Anticancer Agents. J Med Chem (2015) 0.90
Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology. Mol Inform (2014) 0.90
Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Bioorg Med Chem Lett (2012) 0.90
Exploration of a series of 5-arylidene-2-thioxoimidazolidin-4-ones as inhibitors of the cytolytic protein perforin. J Med Chem (2013) 0.90
Docking Screens for Novel Ligands Conferring New Biology. J Med Chem (2016) 0.90
CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway. ACS Med Chem Lett (2011) 0.89
The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PLoS One (2012) 0.89
Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening. ChemMedChem (2010) 0.89
NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem Rev (2014) 0.89
MTiOpenScreen: a web server for structure-based virtual screening. Nucleic Acids Res (2015) 0.88
Titration-based screening for evaluation of natural product extracts: identification of an aspulvinone family of luciferase inhibitors. Chem Biol (2011) 0.88
Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of Plasmodium falciparum macrophage migration inhibitory factor. J Med Chem (2012) 0.88
Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A (2015) 0.88
Breaking a pathogen's iron will: Inhibiting siderophore production as an antimicrobial strategy. Biochim Biophys Acta (2015) 0.88
Monitoring drug promiscuity over time. F1000Res (2014) 0.88
On the use of 2,5-dimethyl-pyrrol-1-yl-benzoic acid derivatives as EPH-ephrin antagonists. J Virol (2014) 0.88
Determining the Degree of Promiscuity of Extensively Assayed Compounds. PLoS One (2016) 0.88
The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable. PLoS One (2014) 0.87
Total synthesis, stereochemical assignment, and biological activity of all known (-)-trigonoliimines. J Org Chem (2013) 0.87
The ChEMBL database in 2017. Nucleic Acids Res (2016) 0.86
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening. J Biomol Screen (2012) 0.86
A brief review of recent Charcot-Marie-Tooth research and priorities. F1000Res (2015) 0.86
A leap into the chemical space of protein-protein interaction inhibitors. Curr Pharm Des (2012) 0.86
Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J Med Chem (2013) 0.86
The emerging role of lysine methyltransferase SETD8 in human diseases. Clin Epigenetics (2016) 0.86
Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol (2013) 0.86
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest (2016) 0.86
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver. Eur J Med Chem (2014) 0.85
High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J Biomol Screen (2013) 0.85
A screening cascade to identify ERβ ligands. Nucl Recept Signal (2014) 0.85
Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nat Commun (2015) 0.85
Identification of HIV-1 inhibitors targeting the nucleocapsid protein. J Med Chem (2012) 0.85
Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library. Antimicrob Agents Chemother (2010) 0.85
Nonnucleoside inhibitors of norovirus RNA polymerase: scaffolds for rational drug design. Antimicrob Agents Chemother (2014) 0.85
Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited. Future Sci OA (2017) 0.85
Compound acquisition and prioritization algorithm for constructing structurally diverse compound libraries. ACS Comb Sci (2011) 0.84
A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance. Cell Chem Biol (2016) 0.84
Computational prediction and validation of an expert's evaluation of chemical probes. J Chem Inf Model (2014) 0.84
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol (2014) 0.84
High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skelet Muscle (2014) 0.84
Retracted Structure and mechanism of the essential two-component signal-transduction system WalKR in Staphylococcus aureus. Nat Commun (2016) 0.84
Dimeric cyclohexane-1,3-dione oximes inhibit wheat acetyl-CoA carboxylase and show anti-malarial activity. Bioorg Med Chem Lett (2010) 0.78